What is SRTA's health score?

Strata Critical Medical, Inc. (SRTA) has a TradeApes health score of 37 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is SRTA's estimated fair value?

Based on our 5-year discounted cash flow model, Strata Critical Medical, Inc.'s estimated fair value is $2.95 per share, representing a -49.1% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is SRTA undervalued or overvalued?

Our model currently rates SRTA as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for SRTA... Refresh in a moment for the full analysis.

Strata Critical Medical, Inc. (SRTA)

Healthcare Overvalued low weak

$5.79

Updated: 2026-06-06

TradeApes Score

Financial Strength

15 Stressed

Operating Trend

45 Mixed

Relative Value

50 Mixed

Capital Allocation

20 Stressed

Risk

65 Healthy

Est. Fair Value $2.95

DCF Upside -49.1%

Sector Rank #1955 of 6677

Key Findings

+ Strong revenue growth — sales up more than 20% year over year

Unlock Full Report →

− Very high leverage — net debt/EBITDA above 5×

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.